The Company's portfolio of product candidates includes NT-501, currently in late-stage clinical development for geographic atrophy (GA) associated with atrophic (dry) age-related macular degeneration (AMD) and retinitis pigmentosa (RP), and NT-503, currently in pre-clinical development for wet AMD.

In 2009, Neurotech completed three Phase 2 clinical studies of NT-501 for the treatment GA and RP. In the GA study the Company announced positive results, including the achievement of human proof of concept. In two RP studies, the Company announced consistent and positive biological effects on photoreceptors. All of Neurotech's development programs are based on the Company's proprietary Encapsulated Cell Technology (ECT). ECT uniquely enables the controlled, continuous delivery of biologics directly to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease.